Study of Combination Therapy With LdT Plus Adefovir Versus Adefovir Alone
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00376259 |
Recruitment Status :
Terminated
(The study was not completed as planned and was terminated early with agreement from the European Medicines Agency (EMEA))
First Posted : September 14, 2006
Results First Posted : May 17, 2011
Last Update Posted : June 30, 2011
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Hepatitis B | Drug: telbivudine Drug: adefovir dipivoxil | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 43 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | An Open-label, Multicenter, Randomized Study of Combination Therapy With Oral LDT600 (Telbivudine) Plus Adefovir Dipivoxil Versus Adefovir Dipivoxil Alone in HBeAg-positive Patients With Chronic Hepatitis B Who Are Lamivudine Resistant |
Study Start Date : | January 2007 |
Actual Primary Completion Date : | August 2008 |

Arm | Intervention/treatment |
---|---|
Experimental: Combination therapy
Combination therapy: 600 mg of telbivudine (LdT) by mouth plus 10 mg of adefovir (ADV) by mouth once daily for 96 weeks.
|
Drug: telbivudine
600mg/day oral tablet for 96 weeks Drug: adefovir dipivoxil 10 mg of adefovir by mouth once daily |
Active Comparator: Adefovir monotherapy
Adefovir monotherapy: 10 mg of adefovir by mouth once daily for 96 weeks.
|
Drug: adefovir dipivoxil
10 mg of adefovir by mouth once daily |
- The Proportion of Participants Who Experienced Virologic Breakthrough [ Time Frame: 96 Weeks ]Virologic breakthrough is defined as a minimum of 1 log reduction from baseline followed by a 1 log increase from nadir on at least 2 consecutive visits including the last treatment visit.
- Change From Baseline in Mean Hepatitis B Virus (HBV) DNA Concentration [ Time Frame: Baseline to 12 weeks, 24 weeks, 48 weeks and 60 weeks ]Efficacy was assessed by the change from baseline in mean HBV DNA concentration after 12, 24, 48 and 60 weeks of treatment.
- Percentage of Participants Achieving Specified Clinical and Laboratory Safety Criteria [ Time Frame: 12 week, 24 week, 48 week and 60 weeks ]Undetectable HBV DNA = HBV DNA <300 copies/ml. Serum aminotransferase (ALT) normalization is defined as ALT within normal limits on 2 successive visits for a pt. with an elevated ALT level (>=1.0 x ULN) at baseline (BL). Hepatitis B e antigen (HBeAg) loss is defined as the loss of detectable serum HBeAg in a pt. who was HBeAg +ve at BL. HBeAg seroconversion is defined as HBeAg loss with detectable HBeAb. Hepatitis B surface antigen (HBsAg) loss is defined as the loss of detectable serum HBsAg in a pt. who was HBsAg +ve at BL. HBsAg seroconversion is defined as HBsAg loss with detectable HBsAb.
- Proportion of Participants With Treatment-emergent HBV Resistance Mutations Associated With Virologic Breakthrough [ Time Frame: Week 96 ]The study was not completed as planned and was terminated early with agreement from the European Medicines Agency (EMEA). Patients did not receive 96 weeks of treatment. Therefore, the primary objective of evaluating virologic breakthrough by Week 96 could not be assessed. Consequently, all protocol-specified inferential analyses on the primary endpoint and all other key secondary efficacy endpoints could not be performed.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 70 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Documented compensated chronic hepatitis B defined by a clinical history compatible with chronic hepatitis B.
- Previous or current lamivudine treatment
- HBV DNA > 6 log10 copies/mL
- Evidence of viral breakthrough
Other protocol-defined inclusion criteria may apply.
Exclusion Criteria:
- Patient is pregnant or breastfeeding.
- Patient is co-infected with hepatitis C virus (HCV), hepatitis D virus (HDV), or HIV.
- Patient has received any anti-HBV treatment for HBV infection other than lamivudine in the 12 months before Screening for this study.
Other protocol-defined exclusion criteria may apply.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00376259
United States, California | |
Novartis | |
San Diego, California, United States | |
San Mateo, California, United States | |
Hong Kong | |
Pok Fu Lam, Hong Kong | |
Korea, Republic of | |
Seoul, Korea, Republic of | |
Taiwan | |
Novarits | |
Kaohsuing, Taiwan | |
Thailand | |
Bangkok, Thailand |
Responsible Party: | Novartis |
ClinicalTrials.gov Identifier: | NCT00376259 |
Other Study ID Numbers: |
CLDT600A2304 |
First Posted: | September 14, 2006 Key Record Dates |
Results First Posted: | May 17, 2011 |
Last Update Posted: | June 30, 2011 |
Last Verified: | June 2011 |
lamivudine resistance Hepatitis B virus |
Hepatitis A Hepatitis B Hepatitis Liver Diseases Digestive System Diseases Hepatitis, Viral, Human Virus Diseases Enterovirus Infections Picornaviridae Infections RNA Virus Infections Hepadnaviridae Infections |
DNA Virus Infections Adefovir Adefovir dipivoxil Telbivudine Antiviral Agents Anti-Infective Agents Reverse Transcriptase Inhibitors Nucleic Acid Synthesis Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-Retroviral Agents |